Oxley Bridge Acquisition Limited Announces the Pricing of $220,000,000 Initial Public Offering
The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution. The Company's primary focus, however, will be to search globally for a target with operations or prospects focusing on global consumer and technology sectors with disruptive growth potential through the use of technology that can benefit from operations in Asia, excluding the People's Republic of China, Hong Kong and Macau.
The Company's management team is led by Jonathan Lin, its Chief Executive Officer and Chairman of the Board of Directors (the 'Board'), and Gary Chan, its Chief Financial Officer. The Board also includes Norma Chu, Enrique Gonzalez, Gan Wee Leong, and Jack Cho.
Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering.
The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York, New York 10022, or by email at prospectus@cantor.com,or by accessing the SEC's website, www.sec.gov.
A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission ('SEC') and became effective on June 24, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements,' including with respect to the expected closing of the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all.
Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the 'Risk Factors' section of the Company's registration statement and prospectus for the Company's initial public offering filed with the SEC. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Contacts
Oxley Bridge Acquisition LimitedJonathan Linjonathan.lin@l2capm.com(778)-653-3584
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Berenberg Upgrades Autodesk (ADSK) Stock to Buy from Hold
Autodesk, Inc. (NASDAQ:ADSK) is one of the Top 10 AI and Technology Stocks to Buy According to Analysts. On June 27, Berenberg upgraded the company's stock to 'Buy' from 'Hold' with a price objective of $365, an increase from the prior target of $325, as reported by The Fly. The firm noted a compelling margin-expansion opportunity at Autodesk, Inc. (NASDAQ:ADSK). Unlike earlier AI tools, which simply improved user productivity, the AI agents have the ability to execute business tasks with full autonomy and agency, according to the firm's analyst. A software engineer using AutoCAD Civil 3D to create a 3D design in a modern office setting. The firm believes that this technological advance unlocks fundamental new value in AI adoption for enterprises, and this trend can benefit Autodesk, Inc. (NASDAQ:ADSK). The company is focusing its growth investments on the strategic priorities in cloud, platform, and AI. Furthermore, it continues to optimize its sales and marketing and has been investing to enable future optimization, which fuels higher margins. For Q2 2026, Autodesk, Inc. (NASDAQ:ADSK) expects revenue in the range of $1,720 million – $1,730 million, and EPS (GAAP) of between $1.37 – $1.46. Autodesk, Inc. (NASDAQ:ADSK) is a leading AI and technology business because it is engaged in developing advanced software platforms for engineering, design, and manufacturing. The company uses AI for the automation of design processes and optimization of construction planning. Parnassus Investments, an investment management company, released its Q3 2024 investor letter. Here is what the fund said: 'In Software, we added Autodesk, Inc. (NASDAQ:ADSK) and Cloudflare while exiting We believe Autodesk's dominant position in architecture, engineering and construction software allows it to increase margins and offer attractive revenue growth. Autodesk is a market-leading vertical software company with the ability to meaningfully improve its margins, while its revenue growth should accelerate as it completes its sales channel re-alignment.' While we acknowledge the potential of ADSK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADSK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below.
Business Wire
43 minutes ago
- Business Wire
IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million
EVRY, France--(BUSINESS WIRE)--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024. Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth, comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025, on its results for the 2024 financial year. This decline is the result of reduced activity of over 40% on the Institut Pasteur's Mutualized Microbiology platform, linked to the drop in epidemiological sequencing, as well as to the decline in projects carried out on the Evry genomics platform, down by around 31%. This decline is the result of delays in the start-up of two major projects, the first samples of which were received by the company in May, as well as a general slowdown in research projects for academic and hospital customers. The company believes that the second half of the year, with the acceleration of major projects (notably UMBRELLA) and improved funding conditions for public research, should enable the situation to improve from the third quarter onwards. As of June 30 th, available cash, including the remainder on the loan granted to the parent company OncoDNA and repaid over the course of 2025, stood at €2.1m. The company used up €0.9m of cash in the first half of 2025, and at this rate may not have enough cash to ensure its financing for the next 12 months. In this context, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the Company is not maintaining its revenue growth forecasts for 2025. Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "The first half of the year has been extremely difficult, with both a sharp drop in academic and hospital research projects, linked to a reduction in public research financing, as well as a reduction in the budgets of several biotech companies in a sector affected by the general economic climate. Despite several successes such as the UMBRELLA project, whose operational launch was announced last month, IntegraGen needs to find new sources of funding to be able to ensure the continuity of its operations." Investors are invited to carefully read section 4.2 of the 2024 Management Report on 'Principal risks and uncertainties facing the Company'. Financial results for the first half of 2025 will be published in October. ABOUT INTEGRAGEN IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 40 employees and generated €8.5 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).
Yahoo
an hour ago
- Yahoo
NVIDIA Corporation (NVDA) Insiders Cash Out Over $1 Billion In Stock Amid Market Surge: Report
NVIDIA Corporation (NASDAQ:NVDA) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. The company's insiders have sold over $1 billion worth of stock over the past year, with a significant uptick in recent weeks as executives capitalize on the surging investor interest, the Financial Times reported on Sunday. A close-up of a colorful high-end graphics card being plugged in to a gaming computer. Over $500 million of the shares were sold in June, as the company's share price reached a record high on Wednesday. The sellers included NVIDIA Corporation (NASDAQ:NVDA)'s CEO, Jensen Huang, who sold shares last week for the first time since September 2024. NVIDIA Corporation (NASDAQ:NVDA)'s shares have staged a remarkable comeback after China's DeepSeek sparked a massive selloff earlier in the year and stoked concerns that AI infrastructure outlays were set to slow down. The stock has soared over the past couple of months as doubts about big tech spending subside. Easing trade tensions between the U.S. and China, and a broadening customer base have also helped the rebound. NVIDIA Corporation (NASDAQ:NVDA) rose 1.72% on Friday to close at $157.75. It ended the week with a market cap of nearly $3.85 trillion. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
